Cole S P, Campling B G, Atlaw T, Kozbor D, Roder J C
Mol Cell Biochem. 1984 Jun;62(2):109-20. doi: 10.1007/BF00223301.
The technology for the production of murine monoclonal antibodies has been refined enormously since its introduction in 1975. However, the technology for generating human monoclonal antibodies has only recently come into its own. In this review, three currently available approaches to the production of human monoclonal antibodies are described. These include the hybridoma technique, based on the fusion of antibody-producing human B lymphocytes with either mouse or human myeloma or lymphoblastoid cells; the EBV immortalization technique, based on the use of Epstein-Barr virus (EBV) to 'immortalize' antigen-specific human B lymphocytes; and the EBV-hybridoma technique, based on a combination of the first two methods. The EBV-hybridoma system retains the advantageous features of the other two systems while overcoming their pitfalls and may be the current method of choice for producing human monoclonal antibodies with a defined specificity.
自1975年引入以来，鼠单克隆抗体的生产技术已得到极大改进。然而，人单克隆抗体的生产技术直到最近才成熟起来。在这篇综述中，描述了目前三种生产人单克隆抗体的可用方法。这些方法包括杂交瘤技术，该技术基于产生抗体的人B淋巴细胞与小鼠或人骨髓瘤细胞或淋巴母细胞系的融合；EBV永生化技术，该技术基于使用爱泼斯坦-巴尔病毒（EBV）使抗原特异性人B淋巴细胞“永生化”；以及EBV-杂交瘤技术，该技术基于前两种方法的结合。EBV-杂交瘤系统保留了其他两个系统的有利特征，同时克服了它们的缺陷，可能是目前生产具有明确特异性的人单克隆抗体的首选方法。
